Jazz Pharmaceuticals (STU:J7Z) Other Operating Expense : €568 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Jazz Pharmaceuticals Other Operating Expense?

Jazz Pharmaceuticals's Other Operating Expense for the three months ended in Mar. 2024 was €143 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €568 Mil.

Jazz Pharmaceuticals's quarterly Other Operating Expense declined from Sep. 2023 (€145 Mil) to Dec. 2023 (€139 Mil) but then increased from Dec. 2023 (€139 Mil) to Mar. 2024 (€143 Mil).

Jazz Pharmaceuticals's annual Other Operating Expense increased from Dec. 2021 (€465 Mil) to Dec. 2022 (€566 Mil) but then declined from Dec. 2022 (€566 Mil) to Dec. 2023 (€558 Mil).

Jazz Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for Jazz Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Other Operating Expense Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

319.33

213.37

465.31

565.62

557.80

Jazz Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Operating Expense	Get a 7-Day Free Trial															139.90	140.35	145.13	138.97	143.27

Jazz Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €568 Mil.

Jazz Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (STU:J7Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (STU:J7Z) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

JAZZ:USA JAZZ:Mexico J7Z:Germany

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (STU:J7Z) Headlines

No Headlines